GLYATL2 is a mitochondrial and endoplasmic reticulum-localized acyltransferase that catalyzes the conjugation of fatty acyl-CoA substrates to the N-terminus of glycine, producing N-acyl glycines 1. The enzyme efficiently conjugates medium- and long-chain acyl-CoAs (C8:0-CoA to C18:0-CoA), with preferential activity toward monounsaturated oleoyl-CoA (C18:1-CoA) and arachidonoyl-CoA, while showing no activity toward C22:6-CoA 12. N-acyl glycines produced by GLYATL2 exhibit antinociceptive, anti-inflammatory, and antiproliferative effects, and activate G-protein-coupled receptors, suggesting roles in lipid signaling and immune response 1. GLYATL2 shows tissue-specific expression with highest levels in salivary gland and trachea, and is also expressed in spinal cord, skin fibroblasts, and Moll glands of the eyelid 13. Clinically, GLYATL2 expression is downregulated in type 2 diabetes 4, suggesting a potential role in glucose and lipid metabolism. GLYATL2 functions as an ETV1 target gene in prostate cancer 56 and is incorporated into prognostic signatures for breast cancer and lung squamous cell carcinoma 78, indicating involvement in cancer progression and metabolic dysregulation associated with malignancy.